

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



撥康視云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

CHANGE OF AUDITORS

This announcement is made by Cloudbreak Pharma Inc. (the “**Company**”; together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

RESIGNATION OF AUDITORS

The board of directors of the Company (the “**Board**”) announces that PricewaterhouseCoopers (“**PwC**”) has resigned as the auditors of the Company with effect from 27 November 2025.

As the Company and PwC could not reach a consensus on the audit fee in respect of the audit of the consolidated financial statements of the Group for the financial year ending 31 December 2025 (“**FY 2025**”), at the request of the Company, PwC has agreed to resign as the auditors of the Company.

The Board and the audit committee of the Company (the “**Audit Committee**”) have reviewed the audit fee proposal provided by PwC and consider that the proposed fee may not be competitive considering the current scale of the Group’s operations, the fee rates offered by other professional accounting firms in the market which possess necessary capabilities and competence (including technical know-how, industry knowledge and track record, manpower and other resources) and the cost control measures of the Group. The Board and the Audit Committee therefore consider that it would be appropriate to change the auditors of the Company.

The Company is incorporated under the laws of the Cayman Islands and there is no requirement under the laws of the Cayman Islands for a resigning auditor to confirm whether or not there is any circumstance connected with its resignation which it considers should be brought to the attention of the holders of securities of the Company. PwC has therefore not issued such confirmation.

The Board and the Audit Committee confirm that, other than the fact that the Company and PwC could not reach a consensus on the audit fee for FY 2025, there is no disagreement between the Company and PwC, and there are no other matters in relation to the resignation of PwC that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board further confirmed that, as at the date of this announcement, PwC has not commenced any audit work on the financial statements of the Group for FY 2025. It is therefore expected that the change of auditors will not materially affect the annual audit of the Group or the release of the annual results of the Group for FY 2025.

The Board would like to take this opportunity to express its sincere gratitude and appreciation to PwC for its professional and quality services rendered for the Group during its tenure of office.

APPOINTMENT OF AUDITORS

The Board further announces that, with the recommendation of the Audit Committee, HLB Hodgson Impey Cheng Limited (“**HLB**”) has been appointed as the auditors of the Company with effect from 27 November 2025 to fill the casual vacancy following the resignation of PwC. HLB shall hold office until the conclusion of the next annual general meeting of the Company.

Having considered a number of factors in assessing the appointment of HLB, including but not limited to: (i) its proposed fee and audit proposal; (ii) its audit experience, industry knowledge and technical competence in handling audit work for companies listed on the Stock Exchange; (iii) its independence from the Group and objectivity; (iv) its reputation in the market and track record; (v) its resources and capabilities, including manpower, time commitment and composition of audit working team; and (vi) compliance with the relevant guidelines issued by the Accounting and Financial Reporting Council, the Board and the Audit Committee are of the view that HLB is independent, competent and capable to act as the auditors of the Company.

The Board and the Audit Committee are also of the view that the change of auditors would not have any material impact on the Group and would enable the Company to enhance the cost-effectiveness of the Group’s audit, and hence is in the interest of the Company and its shareholders as a whole.

The Board would like to take this opportunity to express its warm welcome to HLB on its appointment as the auditors of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 27 November 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Mr. Lai Hin Wing Henry Stephen, Ms. Nie Sijiang and Mr. Ma Yiu Ho Peter as independent non-executive directors.

* For identification purpose only